AliveDx
Manufacturing · Switzerland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Terre Bonne Route De Crassier 13, Eysins...Website
www.alivedx.comRevenue
$108.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About AliveDx
AliveDx is an Eysins, Switzerland-based in-vitro diagnostics company formerly known as Quotient Suisse, with over 30 years of experience developing and manufacturing diagnostic reagents and automated testing solutions for clinical and laboratory environments. The company's product portfolio includes Alba, a blood bank reagents line for hospitals and transfusion centers; MosaiQ, a next-generation continuous random-access immunoassay platform that performs multiplexed, multimodality automated testing to shorten time-to-diagnosis; and LumiQ, an all-in-one immunofluorescence solution for autoimmune disease screening and identification. AliveDx serves laboratorians and clinicians globally, with a mission to simplify laboratory workflows, accelerate disease detection, and improve clinical decision-making. The company operates across Europe, North America, and Asia, and has an active international distribution network spanning markets including Turkey, Indonesia, Singapore, and Algeria.Explore more
AliveDx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AliveDx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once AliveDx has new funding data
Earning: See what the market has to say on AliveDx recently announced quarterly report
Product Launch: Get notified when AliveDx launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if AliveDx is spiking on competitors!
AliveDx, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if AliveDx had a recent Job posting/layoffs
Check if AliveDx has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at AliveDx
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined AliveDx as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
AliveDx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AliveDx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AliveDx.
AliveDx Tech Stack
A closer look at the technologies used by AliveDx
Most Recent Scoops
Open Position
Hiring Plans
AliveDx has more open roles in Operations than it has had at any time in the past 6 months. Areas of expertise include: Cross-Functional Collaboration, Six Sigma Methodology, Manufacturing Processes, Technology Transfer, Corrective Action Management, Continuous Improvement Process, and Manufacturing Operations.
Hiring Plans
Open Position
Open Position
Left Company
Executive Move
Executive Moves, Left Company
AliveDx News & Media
AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.
EYSINS, Switzerland, Sept. 3, 2025 /PRNewswire/ -- AliveDx, the global in-vitro diagnostics company that aims to transform patient care, today announces that it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Vasculitis...AliveDx registers MosaiQ®, its Instrument for Multiplex Testing of Autoimmune Diseases, Allergies and Beyond, as a Class II Exempt Device with the U.S. Food and Drug Administration (FDA)
The MosaiQ instrument is a next-generation, continuous random-access immunoassay platform offering labs automation, simple workflows, fast, multiplexed results and actionable insights for complex-to-diagnose conditions. EYSINS, Switzerland, Aug. 26, 2025 /PRNewswire/ -- AliveDx, the...AliveDx registers MosaiQ®, its Instrument for Multiplex Testing of Autoimmune Diseases, Allergies and Beyond, as a Class II Exempt Device with the U.S. Food and Drug Administration (FDA)
The MosaiQ instrument is a next-generation, continuous random-access immunoassay platform offering labs automation, simple workflows, fast, multiplexed results and actionable insights for complex-to-diagnose conditions. EYSINS, Switzerland, Aug. 26, 2025 /PRNewswire/ -- AliveDx, the...AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) multiplex microarray
EYSINS, Switzerland, April 3, 2025 /PRNewswire/ -- Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) microarray. The MosaiQ AiPlex CTDplus multiplex assay,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AliveDx
Sign Up For FreeTo access detailed company insights
AliveDx is an Eysins, Switzerland-based in-vitro diagnostics company formerly known as Quotient Suisse, with over 30 years of experience developing and manufacturing diagnostic reagents and automated testing solutions for clinical and laboratory environments. The company's product portfolio includes Alba, a blood bank reagents line for hospitals an... Read More
